In medicine, a biomarker is anything used to determine the presence or development of a particular disease or biological state. They can be used to determine if an injury or disease has occurred, or even if a therapy is working. In this episode, Dr. Kendall Van Keuren-Jensen, a Professor in TGen Neurogenomics Division and Co-Director of TGen’s Center for Noninvasive Diagnostics, discusses how her team is working on ways to use biomarkers — in this case the molecular readout of RNA — as a non-invasive method for studying and treating complex diseases, such as those that affect the nervous system.

Nature vs. nurture? How about nature and nature? Dr. Candace Lewis, a postdoctoral fellow in the Huentelman lab at TGen, walks us through a biological regulatory framework known as epigenomics that changes the behavior of our cells due to our life experiences. Dr. Lewis also discusses the resurgence in psychedelic assisted therapy to treat depression and trauma, and her work in Autism.

Helios Scholar Mario Mosqueda asked 10 TGen scientists for their best career advice in an insightful discussion on charting a path in science.

Did You Know? There are fellows - and ladies - that work in the lab to learn how to lead a lab. They're called 'postdocs.'

Steve, a four-year pancreatic cancer, survivor shares his story of hope.

Students from the inaugural TGen Bioscience Leadership Academy took over the TGen Talks podcast to discuss what they learned during their two-week, immersive summer experience at TGen.

Single-Cell Sequencing promises to bring more precision to 'precision medicine.' Learn how this new technique could revolutionize diagnosis and treatment from Dr. Jonathan Keats.

James Lowey, TGen's Chief Information Officer, discusses how high-performance computing has revolutionized genomics and how our partnership with Dell has created a powerful platform to transform health.

Dr. Jessica Lang, a mother-to-be, discusses a new treatment discovery for ovarian cancer, the deadliest reproductive cancer.

Dr. Jonathan Keats discusses how multiple myeloma can be multiple cancers from a genetic standpoint. Through his work with the Multiple Myeloma Research Foundation's CoMMpass Study, Dr. Keats' team has sequenced 1,150 patients from 90 sites worldwide. What does this mean for patients?